Rational in situ programming of cancer vaccine-responding T-cell clones

癌症疫苗反应 T 细胞克隆的合理原位编程

• 批准号: 10412138
• 负责人: Matthias Stephan
• 金额: $ 46.42万
• 依托单位: FRED HUTCHINSON CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10412138
• 关键词: 3-Dimensional; Adjuvant; Affinity; Age; Antibodies; Antigens; Antitumor Response; B-Lymphocytes; Binding; Biomedical Engineering; CD28 gene; CD4 Positive T Lymphocytes; CD8-Positive T-Lymphocytes; CD8B1 gene; Cancer Patient; Cancer Vaccine Related Development; Cancer Vaccines; Chimeric Proteins; Clinic; Clinical Research; Clone Cells; Custom; Data; Databases; Disease; Engineering; Ensure; Epitopes; Frequencies; Gene-Modified; Genes; Goals; Homeostasis; Human; Immune; Immune response; Immune system; Immunity; Immunization; Immunize; Immunologist; In Situ; Individual; Information Systems; Injectable; Intramuscular; KPC model; Knowledge; Ligands; Lymph; Lymphocyte; MHC Class II Genes; Malignant Neoplasms; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Measures; Memory B-Lymphocyte; Methods; Mus; Pancreatic Ductal Adenocarcinoma; Patients; Peripheral; Persons; Pharmaceutical Preparations; Phenotype; Physicians; Plasmids; Polymers; Population; Provenge; Reagent; Research; Research Proposals; Safety; Self Tolerance; Specificity; Survival Rate; System; T cell receptor repertoire sequencing; T cell response; T memory cell; T-Cell Receptor; T-Cell Receptor Genes; T-Lymphocyte; T-cell receptor repertoire; Techniques; Technology; Testing; Therapeutic; Transgenes; Translations; Tumor Antigens; Tumor Escape; Tumor Immunity; Vaccine Antigen; Vaccines; Wilms Tumor Suppressor 1; activated protein C receptor; anti-cancer; antigen-specific T cells; arm; base; bioinformatics tool; cancer cell; cancer immunotherapy; cancer regression; cancer type; clinical efficacy; clinically relevant; design; engineered T cells; experience; fighting; immunological status; immunoregulation; improved; men; mesothelin; multidisciplinary; nanoparticle; nanoparticle delivery; nanoparticle drug; neoantigens; pancreatic cancer model; programs; receptor; response; side effect; tumor; vaccine failure; virtual

Project Summary Currently no method exists that would allow physicians to rapidly and reliably establish T-cell immunity against tumor antigens. Bioinformatics tools can predict antigens on cancer cells that are recognized by T cells, but the vaccines based on them often fail because the immunized individuals have too few T cells with the appropriate receptors or lack them altogether. The overall goal of our research proposal is to resolve this problem by developing injectable nanoreagents that introduce into the peripheral T-cell repertoire engineered T-cell receptors (TCRs) that optimally bind the most prevalent vaccine epitope. Specifically, we hypothesize that a customized specificity can be programmed into T cell populations by combining anti-cancer vaccines with techniques that genetically enable endogenous CD8 T cells to express TCRs specific for the vaccines. We further hypothesize that we can use this platform to program CD4 T helper cells with defined MHC class-II- restricted TCRs, and thereby improve tumor-specific CD8 lymphocyte and B cell responses to tumor antigens compared to conventional immunization methods. Our multidisciplinary team of immunologists, bioengineers and geneticists has already established that intramuscularly injected nanoparticles can deliver engineered TCR genes into host T cells so they recognize cancer vaccine antigen. Following rapid vaccine-induced expansion, nanoparticle-programmed T cells ultimately differentiate into long-lived memory T cells. Our long-term goal is to develop a full suite of nanoparticles drugs that would allow physicians to rapidly establish anti-cancer immunity by introducing exogenous antigen-specific TCRs into the patient's T-cell pool. As essential steps toward achieving this goal, we propose the following Specific Aims: (1) To test the wider applicability and long- term safety of programming vaccine specificity into CD8+ T cells, (2) to quantify the degree to which host CD4+ T cells programmed with TCRs to cancer-vaccine antigens boost the immune response, and (3) to determine if providing optimized CD4 T-cell help and reversing tumor immune evasion mechanisms enables in situ programmed vaccine-specific T cells to eradicate disease. We believe that data, reagents, and technology systems generated by our research will provide a conceptual framework for the design of a broad repertoire of gene modification systems designed to generate selective immunity against any type of cancer. Using these in the clinic could make cancer vaccines not only more effective, but also reduce the likelihood of vaccine failure.

项目摘要 目前还没有一种方法可以让医生快速而可靠地建立起针对 肿瘤抗原。生物信息学工具可以预测T细胞识别的癌细胞上的抗原，但 基于它们的疫苗经常失败，因为免疫个体的T细胞太少，具有适当的 受体或完全缺乏受体。我们研究提案的总体目标是通过以下方式解决这个问题 将可注射纳米试剂引入外周T细胞库工程T细胞的研究进展 以最佳方式结合最流行的疫苗表位的受体(TCR)。具体地说，我们假设 通过将抗癌疫苗与T细胞群相结合，可以将定制的特异性编程为T细胞 从基因上使内源性CD8T细胞能够表达疫苗特异性TCR的技术。我们 进一步假设，我们可以使用这个平台来编程具有定义的MHC-II类的CD4T辅助细胞- 限制TCR，从而提高肿瘤特异性CD8淋巴细胞和B细胞对肿瘤抗原的反应 与常规免疫方法相比。我们由免疫学家、生物工程师组成的多学科团队 遗传学家已经证实，肌肉内注射的纳米颗粒可以传递工程TCR 基因进入宿主T细胞，这样它们就能识别癌症疫苗抗原。在疫苗诱导的快速扩张之后， 纳米颗粒编程的T细胞最终分化为长寿的记忆T细胞。我们的长期目标是 开发全套纳米药物，使医生能够快速建立抗癌药物 通过将外源抗原特异性TCRs引入患者的T细胞池进行免疫。作为必要的步骤 为了实现这一目标，我们提出了以下具体目标：(1)测试更广泛的适用性和长期- 将疫苗特异性编程到CD8+T细胞的长期安全性，(2)量化宿主 用针对癌症疫苗抗原的TCR编程的CD4+T细胞增强免疫反应，以及(3) 确定提供优化的CD4T细胞帮助和逆转肿瘤免疫逃避机制是否能够在 原位编程疫苗特异性T细胞来根除疾病。我们相信数据、试剂和技术 我们的研究生成的系统将为设计广泛的曲目提供一个概念框架 基因修饰系统旨在产生对任何类型癌症的选择性免疫力。在以下项目中使用这些 该诊所不仅可以使癌症疫苗更有效，还可以降低疫苗失败的可能性。